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Abstract
The DNA genome of a novel HPV genotype, HPV-125, isolated from a hand wart of an immuno-competent 19-year old male
was fully cloned, sequenced and characterized. The full genome of HPV-125 is 7,809-bp in length with a GC content of
46.4%. By comparing the nucleotide sequence of the complete L1 gene, HPV-125 is phylogenetically placed within
cutaneotrophic species 2 of Alphapapillomaviruses, and is most closely related to HPV-3 and HPV-28. HPV-125 has a typical
genomic organization of Alphapapillomaviruses and contains genes coding for five early proteins, E6, E7, E1, E2 and E4 and
two late capsid proteins, L1 and L2. The genome contains two non-coding regions: the first located between the L1 and E6
genes (nucleotide positions 7,137–7,809, length 673-bp) and the second between genes E2 and L2 (nucleotide positions
3,757–4,216, length 460-bp). The E6 protein of HPV-125 contains two regular zinc-binding domains at amino acid positions
29 and 102, whereas the E7 protein exhibits one such domain at position 50. HPV-125 lacks the regular pRb-binding core
sequence within its E7 protein. In order to assess the tissue predilection and clinical significance of HPV-125, a quantitative
type-specific real-time PCR was developed. The 95% limit-of-detection of the assay was 2.5 copies per reaction (range
1.7–5.7) and the intra- and inter-assay coefficients of variation were 0.47 and 2.00 for 100 copies per reaction, and 1.15 and
2.15 for 10 copies per reaction, respectively. Testing of a representative collection of HPV-associated mucosal and cutaneous
benign and malignant neoplasms and hair follicles (a total of 601 samples) showed that HPV-125 is a relatively rare HPV
genotype, with cutaneous tropism etiologically linked with sporadic cases of common warts.
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Introduction
Papillomaviruses (PV) are small non-enveloped viruses with a
double stranded circular DNA genome, approximately 8-kb in
size. So far, 29 genera of papillomaviruses, designated by letters of
the Greek alphabet, have been described, of which 5 genera
(Alpha-, Beta-, Gamma-, Mu- and Nupapillomavirus) contain members
that can infect humans and are referred to as human
papillomaviruses (HPV) [1,2]. HPV genotypes that represent
natural papillomavirus taxonomic entities, are grouped into HPV
species according to their tissue tropism, sequence similarity, and
other distinct biological properties. In order to be recognized as a
distinct genotype, the entire L1 open reading frame (ORF) of a
candidate HPV isolate must differ by at least 10% from all other
officially recognized HPV genotypes [1,2] and the entire genome
of the novel genotype must be deposited, in the form of one or
more clones, in the Reference Centre for Papillomaviruses in
Heidelberg, Germany, so that the full genomic sequence can be
independently confirmed. If these two conditions are met, the
novel genotype is assigned a consecutive number, based on its
order of submission, by the Reference Centre.
To date, more than 150 HPV genotypes have been fully
characterized; roughly a third of them have been discovered since
2004, mostly by the use of molecular methods [1,2]. Based on the
large number of partial sequences published in the last few years,
the final characterization of many further new HPV genotypes is
expected in the near future [3,4]. The majority of officially
recognized HPV genotypes have been etiologically linked to
specific diseases, such as various forms of cancer, common and
genital warts and other benign and malignant mucosal and skin
lesions [5]. Most notably, infection with several genotypes of
Alphapapillomavirus species 7 (type species HPV-18) and 9 (type
species HPV-16) is strongly associated with the development of
cervical carcinoma and other cancers in the anogenital region of
both genders [5,6], while infection with members of Alphapapillo-
mavirus species 10 (type species HPV-6) is associated with the
development of benign tumors such as genital warts and laryngeal
papillomas [5]. Another common HPV-associated clinical entity,
verrucae vulgaris, or common warts, is caused by members of
Alphapapillomavirus species 2 and 4, and several species of Gama-,
Mu- and Nupapillomavirus genera [7]. Members of Alphapapillomavirus
species 2 were first found in patients with the hereditary disorder
epidermodysplasia verruciformis [8] and are most frequently associated
with flat or plane and intermediate skin warts in immuno-
competent individuals [9–11]. In immuno-suppressed patients,
such as solid-organ recipients, these genotypes are also associated
or can co-localize with dysplastic warts and non-melanoma skin
cancer [12–15].
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e22414In this study, a novel HPV genotype, isolated originally from a
hand wart (isolate SIBX9) and initially characterized by our group
in 2004 [16], was characterized fully and deposited in the
Reference Centre for Papillomaviruses in Heidelberg, Germany,
where it was assigned its official name, HPV-125. In addition, a
quantitative type-specific real-time PCR (RT-PCR) was developed
and a representative collection of HPV-associated benign and
malignant neoplasms and hair follicles was tested in order to assess
the tissue predilection and clinical significance of HPV-125.
Materials and Methods
Amplification and sequencing of initial 474-bp sequence
of the HPV-125 L1 gene
The total DNA from the original clinical sample of a hand wart
containing HPV-125 was extracted using a High Pure PCR
Template Preparation kit (Roche Applied Science, Mannheim,
Germany), according to the manufacturer’s instructions [16]. The
initial 474-bp sequence of the HPV-125 L1 gene (GenBank Acc.
No: AJ810860, corresponding to nucleotide positions 5,994–6,468
of the HPV-125 complete genome) was obtained by the use of
primers HVP2 (59-TCNMGNGGNCANCCNYTNGG-39 [14])
and B5 (59- AYNCCRTTRTTRTGNCCYTG -39 [13]) and
FastStart Taq DNA polymerase kit (Roche Applied Science) on a
PE9700 Thermo Cycler (Applied Biosystems, Foster City, CA).
PCR was carried out in a 25 ml reaction volume containing 5 ml
(100 ng) of extracted DNA, 2.5 mlo f1 0 6PCR Reaction Buffer,
200 mM (each) of dATP, dCTP, dGTP, and dTTP, 1.5 mM of
MgCl2, 1.25 U of FastStart Taq DNA Polymerase, and 25 pmol
of each primer. The thermal cycler program was set to 4 min at
94uC, followed by 40 cycles consisting of 1 min at 95uC, 2 min at
52uC and 1 min at 72uC. The final extension step was performed
at 72uC for 4 min and the reaction mixtures were then cooled to
4uC. Sequencing of the 474-bp PCR fragment was done by using
the primers HVP2 and B5 on the ABI PrismH 310 Genetic
Analyzer System (Applied Biosystems) and Big DyeH Terminator v
1.1 Cycle Sequencing Kit (Applied Biosystems).
Amplification, sequencing and cloning of the complete
genome of HPV-125
Primers for the reverse long template PCR (125-fpw2 and 125-
rpw2, Table S1) were constructed manually on the basis of the
previously obtained 474-bp sequence of the HPV-125 L1 gene. A
7,770-bp PCR fragment was obtained from the original clinical
sample by using the Expand Long Template PCR System (Roche
Applied Science) on a PE9700 Thermo Cycler (Applied
Biosystems). PCR was carried out in a 25 ml reaction volume
containing 7.1 ml of extracted DNA, 2.5 mlo f1 0 6Expand Long
Template buffer 2 with 27.5 mM MgCl2, 500 mM (each) of dATP,
dCTP, dGTP, and dTTP, 0.75 U of Expand Long Template
Enzyme Mix, and 3 pmol of each primer. The thermal cycler
program was set to 2 min at 94uC, followed by 40 cycles consisting
of 10 s at 94uC, 30 s at 58uC and 9 min at 68uC. The final
extension step was performed at 68uC for 10 min and the reaction
mixtures were then cooled to 4uC. Sequencing of the 7,770-bp
PCR fragment was done by primer walking with 38 primers
(Table S1) by using the ABI PrismH 310 Genetic Analyzer System
(Applied Biosystems) and Big DyeH Terminator v 1.1 Cycle
Sequencing Kit (Applied Biosystems). The full genome sequence of
HPV-125 was deposited in GenBank through EMBL in
September 2009 and can be accessed under acc. no. FN547152.
PCR fragments for the cloning of the full genome of HPV-125
were prepared with the Expand Long Template PCR System
(Roche Applied Science) from the original clinical sample using
sequencing primer pairs 125-fpw5 and 125-rpw6, and 125-fpw14
and 125-rpw 15 (Table S1), giving 4,594-bp and 5,140-bp
overlapping PCR fragments, respectively. Both PCR fragments
were sequenced and their sequences were found to be identical to
that of the larger 7,700-bp PCR fragment. Both PCRs were
carried out in a 25 ml reaction volume containing 5 ml of extracted
DNA, 2.5 mlo f1 0 6 Expand Long Template buffer 2 with
27.5 mM MgCl2, 500 mM (each) of dATP, dCTP, dGTP, and
dTTP, 0.75 U of Expand Long Template Enzyme Mix, and
3 pmol of each primer. The thermal cycler program was set to
2 min at 94uC, followed by 40 cycles consisting of 10 s at 94uC,
30 s at 56uC and 6 min at 68uC. The final extension step was
performed at 68uC for 10 min and the reaction mixtures were
then cooled to 4uC.
Before cloning, PCR products were run on gel electrophoresis,
excised and purified from 1% agarose gel using a GeneJET
TM Gel
Extraction Kit (Fermentas, Vilnius, Lithuania). Plasmid clones
containing overlapping PCR products were prepared using a
CloneJET
TM PCR Cloning Kit (Fermentas) according to the
manufacturer’s instructions. TransformAid
TM Bacterial Transfor-
mation Kit (Fermentas) was used to transform E.coli strain JM107
with the plasmids, according to the manufacturer’s instructions.
Plasmid clones isolated from the transformed overnight
bacterial culture with the GeneJET
TM Plasmid Miniprep Kit
(Fermentas) were checked for correct inserts by size analysis and
sequencing with the pJET1.2 sequencing primers, according to the
manufacturer’s instructions. Full sequencing by primer walking
was carried out for two clones, confirming the previously
determined full sequence of the HPV-125 genome. Both clones,
together covering the full genome of HPV-125, were deposited in
the Reference Centre for Papillomaviruses, Heidelberg, Germany
in September 2009, where they were re-sequenced and the novel
genotype was assigned its number in October 2009.
ORF and phylogenetic analysis
The ORFs of HPV-125 were determined using the ORF finder
function of Vector NTI Advance
TM v 11.0 (Invitrogen, Carlsbad,
CA) and pairwise comparison of genes of closely related HPV
genotypes.
In order to phylogenetically place HPV-125, a multiple
sequence alignment of L1 ORF of HPV-125 and 116 previously
characterized HPV types available [1,2], was constructed using the
Alignment explorer program of the MEGA4 software package
[17,18], at the nucleotide level. All positions containing gaps and
missing data were eliminated from the alignment, leaving 1,171
nucleotide positions in the final dataset.
All further phylogenetic analyses were also conducted by using
MEGA4 [17,18]. The evolutionary history was inferred by using
the Minimum Evolution (ME) method [19]. The evolutionary
distances (in units of the number of base substitutions per site) were
computed by using the Maximum Composite Likelihood method
[18] and the Neighbor-joining algorithm [20] was used to generate
the initial tree. The ME tree was searched using the Close-
Neighbor-Interchange algorithm [21] at a search level of 1.
The optimal tree with the sum of branch length=14,14565449
was used for Figure 1, the tree remaining drawn to scale, with
branch lengths in the same units as those of the evolutionary
distances used to infer the phylogenetic tree. The tree was
bootstrap re-sampled 1,000 times.
Additionally, Maximum Parsimony analysis of the same dataset
was conducted (data not shown), using the Close-Neighbor-
Interchange algorithm to search for the optimal tree, also by using
the MEGA 4 software package, which also grouped HPV-125
within the Alphapapillomavirus species 2.
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genotypes of the Alphapapillomavirus species 2, pairwise sequence
alignments (both nucleotide and amino acid) were carried out and
percentage similarity was calculated for each of the viral genes (E6,
E7, E1, E2, L1 and L2) between HPV-125 and each of the
genotypes for which full genomic sequences were available (HPV-
3, HPV-10, HPV-28, HPV-29, HPV-77, HPV-94 and HPV-117),
by using the BioEdit v7.0.9.0. software package [22].
HPV-125 type specific real-time PCR
The primers 125-RT-L1-F (59- GGTTACCCGACCCAAA-
TAAGT -39, nucleotide positions 5,851–5,871) and 125-RT-L1-R
Figure 1. A consensus phylogenetic tree of 117 HPV L1 sequences. The evolutionary history was inferred using the Minimum Evolution
method [19] and the consensus tree was inferred from 1,000 bootstrap replicates. The evolutionary distances were computed using the Maximum
Composite Likelihood method [18] and are in units of the number of base substitutions per site. Bootstrap values for members of Alphapapillomavirus
species 2 are given above the main tree. The GenBank account numbers of the HPV genotypes are given next to the genotypes’ name, where
available.
doi:10.1371/journal.pone.0022414.g001
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5,891–5,911), specific for HPV-125, were chosen within the L1
gene by using the on-line ProbeFinder software (Roche Applied
Science). FAM-labeled Universal Probe nr. 14 (Roche Applied
Science) was used to detect the specific products in the real-time
reaction.
The plasmid reference clone of HPV-125, containing the entire
L1 sequence, was used to optimize the RT-PCR conditions and to
evaluate the linearity, lower detection limit and reproducibility of
the assay. The number of starting plasmid copies/ml was
calculated from the concentration of plasmid DNA, quantified
using a NanoDrop ND-1000 spectrophotometer (Nanodrop
Technologies, Oxfordshire, UK), as described previously [23].
The optimized RT-PCR reaction mixture contained 10 mlo f
LightCyclerH Probes Master 26 conc. (Roche Applied Science),
0.2 mM of each primer, 0.05 mM of Universal Probe nr. 14 (Roche
Applied Science), 1 U of LightCyclerH Uracil-DNA Glycosylase
(Roche Applied Science), sample DNA and water up to a final
volume of 20 ml. The assay was performed on a LightCyclerH 480
real-time PCR Instrument (Roche Applied Science) under the
following conditions: Uracil-N-Glycosylase activation at 40uC and
pre-incubation at 95uC for 10 min each, followed by 45 cycles at
95uC for 10 s (denaturation) and 60uC for 30 s (annealing/
extension). Acquisition of the fluorescence signal (FAM 465–
510 nm) was performed during each annealing/extension step.
The final cooling step consisted of a 10 s hold at 40uC.
To evaluate the linearity of the RT-PCR assay, ten-fold serial
dilutions of the reference plasmid were prepared in 1.5 ml DNA
LoBind tubes (Eppendorf, Hamburg, Germany) using a water
solution with carrier RNA (1 mg/ml) and tested in triplicate. The
limit of detection of the assay was determined by testing 15
replicates of the reference plasmid dilutions corresponding to an
input of 25, 13, 6, 3, 1.5, 0.8 and 0.4 copies per reaction and
calculated by Probit analysis using SPSS software v.15.0.0.0 (SPSS
GmbH Software, Munich, Germany). Intra- and inter-assay
reproducibility of the RT-PCR were assessed by testing triplicates
of plasmid dilutions corresponding to an input of 100 and 10
copies per reaction, in three independent runs.
To ensure specificity and to check for cross-reactivity of RT-
PCR, 10
7 to 10
8 copies of reference clones or synthetic L1
sequences (inserted into plasmid pUC57, by Genscript, Piscat-
away, USA) of HPV-2, HPV-3, HPV-7, HPV-10, HPV-27, HPV-
28, HPV-29, HPV-40, HPV-43, HPV-77, HPV-78, HPV-91
(kindly provided by E-M. de Villiers, T. Matsukura and R. Burk)
were tested.
Clinical samples
The tissue predilection and clinical significance of HPV-125
were assessed on a representative collection of HPV-associated
benign and malignant neoplasms and hair follicles. The DNA was
isolated from a total of 601 samples obtained from the same
number of patients, including tissue samples of histologically
confirmed cervical squamous cell carcinoma (104), laryngeal
papilloma (85), genital warts (71), common warts (102), squamous
cell carcinoma (SCC) of the skin (52) basal cell carcinoma (BCC) of
the skin (49) and hair follicles (138), as described previously
[24,25]. The quality of isolated DNA and absence of amplification
inhibitors were determined by testing for the 268-bp or 110-bp
fragment of human beta-globin using RT-PCR, as described
previously [24]. The number of diploid human cells for the HPV-
125 positive tissue samples was calculated from the beta-globin
concentration, as described previously [26]. All positive results of
the HPV-125 RT- PCR assay were confirmed by sequencing.
The presence of additional HPV genotypes in HPV-125 positive
samples was determined using two commercial line-probe assays:
RHA skin (beta) HPV (Diassay B.V., Rijswijk, The Netherlands),
which allows identification of 26 different Betapapillomavirus HPV
genotypes, and INNO-LiPA HPV Genotyping Extra (Innoge-
netics, Gent, Belgium), which allows identification of 28 different
Alphapapillomavirus HPV genotypes, and additionally by three
consensus in-house PCRs using Ma/Ha [27], CPI/CPIIs [28] and
GP 5+/6+ [29] primers and sequencing of PCR-products.
Ethics Statement
None of the 601 clinical samples were collected solely for the
purpose of this study. All samples included in the study were
collected in compliance with the Helsinki declaration. Samples of
cervical cancer, hair follicles, genital warts and common warts
were collected prospectively in our previous studies. These studies
were approved by the Ethics Committee of the Ministry of Health
of Republic of Slovenia (Consent references 34/11/06, 83/11/09,
174/05/09, 97/11/09 and 100/12/09) and written informed
consent was obtained for each patient. Samples of laryngeal
papillomas, squamous cell carcinoma and basal cell carcinoma of
the skin were retrieved from the tissue collection of paraffin-
embedded samples of the Institute of Pathology, Faculty of
Medicine, University of Ljubljana. Approval from Institutional
Review Board of the Institute of Pathology, Faculty of Medicine,
University of Ljubljana was obtained prior to starting work on
samples included in this study. In accordance with national
legislation of the Republic of Slovenia no informed consent is
needed for research on archival clinical samples. In order to
protect the identity of the patient, all archival clinical samples used
in the study were coded and tested anonymously. The only
available data were patient gender, age and immune status (if
collected during the original study).
Results and Discussion
HPV-125 was detected in 2004 in the biopsy specimen of a
hand wart obtained from a 19 year-old immuno-competent male
patient at the Department of Dermatovenereology, University
Medical Centre, Ljubljana, Slovenia. It was initially identified as a
putative novel HPV genotype by the use of HVP2/B5 primers
[13,14], designed to detect various cutaneous HPVs, with which a
474-bp sequence of the L1 gene was amplified and sequenced.
This partial L1 sequence was deposited in GenBank as strain
SIBX9 (Acc. No. AJ810860) in August 2004 [16]. In addition to
HPV-125, the original clinical sample also contained genotypes
HPV-8 and HPV-22, as identified by the use of Ma/Ha [27], and
CPI/CPIIs [28] primers and sequencing, respectively.
By using PCR amplification, the complete genome of HPV-125
was cloned and deposited in the Reference Centre for Papilloma-
viruses in Heidelberg, Germany, where the genomic sequence of
HPV-125 was independently confirmed and the novel genotype
was assigned its name in October 2009, according to the
consecutive number of characterization.
The full genome of HPV-125 was determined to be 7,809-bp in
length with a GC content of 46.4%. Phylogenetic comparisons of
the HPV-125 complete L1 sequence with L1 sequences of 116
HPV genotypes place HPV-125 within the Alphapapillomavirus
species 2, closest to HPV-3 and HPV-28 (Figure 1). Additional
pairwise alignment of HPV-125 L1 nucleic acid and amino acid
sequences with corresponding sequences of HPV-3 and HPV-28
(Table 1) revealed that HPV-125 is most closely related to HPV-3.
Further sequence analysis revealed that HPV-125 has a
genomic organization typical of the Alphapapillomavirus genus
Characterization of Human Papillomavirus HPV-125
PLoS ONE | www.plosone.org 4 July 2011 | Volume 6 | Issue 7 | e22414(Figure 2) and contains genes coding for five early proteins E6, E7,
E1, E2 and E4 and two late capsid proteins L1 and L2. The
genome of the HPV-125 also contains two non-coding regions; the
classic non-coding long control region (LCR) located between the
L1 and E6 genes (nucleotide positions 7,137–7,809, length 673-bp)
and a second non-coding region located between genes E2 and L2
(nucleotide positions 3,757–4,216, length 460-bp). Typical features
of the LCR of HPV-125 are shown in Figure 3.
The percentage similarity of nucleotide and amino acid
sequences of the six viral genes of HPV-125 shared by other
HPV genotypes from Alphapapillomavirus species 2 is shown in
Table 1. The nucleotide and amino acid sequences of the late
genes L1 and L2 and the early gene E2 of HPV-125 showed the
highest similarity to the corresponding genes of HPV-3. However,
the early gene E7 of HPV-125 was more similar to E7 of HPV-28,
than to E7 of HPV-3 (Table 1) in both nucleotide and amino acid
sequences. The nucleotide sequence of the early gene E6 of HPV-
125 showed the highest similarity to E6 of HPV-3, while its amino
acid sequence was slightly more similar to the E6 protein of HPV-
28. Similarly, the nucleotide sequence of the early gene E1 of
HPV-125 showed the highest similarity to E1 of HPV-3, while the
amino acid sequence was more similar to the E1 protein of HPV-
28. Given that HPV-3, HPV-28 and HPV-125 are the most
closely related genotypes within Alphapapillomavirus species 2, this
could either reflect a recombination event or a different
evolutionary divergence of the early and late genes of these three
genotypes from their most recent common ancestor.
In silico analysis showed that the E6 protein of HPV-125
contains two regular zinc-binding domains (CxxC(x)29CxxC) at
amino acid positions 29 and 102, whereas the E7 protein of HPV-
125 exhibits one such domain at position 50 (Figure 4). Like
several other genotypes from Alphapapillomavirus species 2 [30],
Table 1. Percentage similarity between E6, E7, E1, E2, L1, L2
genes of HPV-125 and closely related HPVs from species 2 of
Alphapapillomaviruses.
HPV-
125 HPV-3 HPV-10 HPV-28 HPV-29 HPV-77 HPV-94 HPV-117
E6
nt 84.8
a 79.9
a 83.2
a 71.8
a 76.7
a 80.8
a 77.9
a
aa 82.4 73.8 83.0 65.1 74.5 77.9 72.5
E7
nt 90.2
a 86.4 90.9 81.0 81.0 89.4 86.4
aa 81.8 80.7 86.4 73,6 73.6 85.2 78.4
E1
nt 88.6 81.0 86.0 80.9 80.1 80.6 80.9
aa 87.5 79.8 88.1 82.7 80.6 80.3 80.2
E2
nt 86.4 77.8 84.3 75.0 75.7 78.7
a 79.7
aa 82.3 74.0 79.2 69.2 70.0 73.5 74.5
L1
nt 85.4 80.0 83.9 74.4
a 74.3
a 79.3 80.3
aa 90.8 86.4 88.7 81.9 80.0 84.0 85.4
L2
nt 85.6 79.9 82.9 74.8 75.0
a 75.0 76.7
aa 90.1 85.3 87.6 78.6 77.4 80.9 82.0
nt – nucleotide.
aa – aminoacid.
aORFs not equal in length – similarity was calculated from the first common
ATG of the two genotypes.
doi:10.1371/journal.pone.0022414.t001
Figure 2. Genomic organisation of HPV-125. Genomic positions of
viral genes E6, E7, E1, E2, E4 (E1‘E4), L1 and L2 are indicated next to the
respective gene. The non-coding regions located between L1 and E6
(LCR); and E2 and L2 are indicated with a dotted line.
doi:10.1371/journal.pone.0022414.g002
Figure 3. Characteristic features of the long control region (LCR) of HPV-125. The genomic locations of E2 binding sites (ACC-N5–7-GGT),
polyadenilation sites (AATAAA), and TATA signals (TATAAA or TATA(A/T)A(A/T)) are indicated on the coding strand.
doi:10.1371/journal.pone.0022414.g003
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[8,10–12,30,31] within its E7 protein (Figure 4).
HPV-125, similarly to HPV-28 possesses an approximately 300-
bp long E4 ORF at genomic location 3,215–3,517. However, it is
likely that the E4 protein of HPV-125 is actually translated from a
spliced mRNA consisting of the first few codons of the E1 ORF
joined to the E4 ORF (E1‘E4 CDS consisting of genomic positions
693..708 and 3,237..3,517 nt) as was determined for other better-
characterized Alphapapillomaviruses.
Unlike most HPV genotypes from genus Alphapapillomavirus,
which have a mucosal tropism, members of Alphapapillomavirus
species 2 (HPV-3, HPV-10, HPV-28, HPV-29, HPV-77, HPV-78,
HPV-94 and HPV-117) exhibit cutaneous tropism [8–12,14,30].
The two genotypes of species 2, HPV-3 and HPV-10, were among
the first HPVs to be characterized and were both isolated from
scrapings of hand lesions, resembling flat warts, from immuno-
compromised individuals with epidermodysplasia verruciformis [8]. In
addition, these two genotypes were later found to be associated
with flat warts of immuno-compromised, as well as immuno-
competent individuals [9]. HPV-28 was first found in a case of
butcher’s warts [10], while HPV-29 was first detected in a
common skin wart [11]. HPV-77 was first isolated from a benign
wart but has also been found in several cases of dysplastic warts
and SCC of the skin in renal-transplant recipients [12]. HPV-94
(DL40) was isolated from malignant skin tumor of a renal-
transplant recipient [15]. HPV-117 was isolated from a common
wart of an organ-transplant recipient, and was shown to be
persistent over 24 months [30]. Based on the data acquired so far
[8–12,14,30], members of Alphapapillomavirus species 2 seem to be
associated predominantly with flat and common warts in immuno-
competent individuals, while some genotypes belonging to this
species also have the potential to cause malignant transformation
in immuno-compromised hosts.
In order to assess the biological and clinical importance of HPV-
125, a quantitative HPV-125 type-specific RT-PCR assay was
developed, based on amplification of a 61-bp region of the HPV-
125 L1 gene (Table S1). The standard curve of the assay showed an
excellent correlation coefficient (R
2=1.00) between the Ct
(threshold) and the log of starting viral copy number, across at
least seven orders of magnitude. The 95% limit of detection of the
assay was 2.5 copies per reaction (range 1.7–5.7) and the intra and
inter-assay coefficient of variation (CV (%)=(st.dev/mean Ct)*100)
was 0.47 and 2.00 for 100 copies per reaction, and 1.15 and 2.15 for
10 copies per reaction, respectively. The assay showed no cross-
Figure 4. Amino acid alignment of HPV-125 E6 and E7 proteins with corresponding proteins of closely related genotypes from
Alphapapillomavirus species 2 and genotypes HPV-16, HPV-18, HPV-6 and HPV-11. Black boxes indicate the location of zinc-binding
domains (CxxC(x)29CxxC) in both E6 and E7 amino acid alignments. The purple box indicates the location of the pRb-binding core sequence (LxCxE),
absent in several Alphapapillomavirus species 2 genotypes [30], including HPV-125.
doi:10.1371/journal.pone.0022414.g004
Table 2. Clinical samples tested for the presence of HPV-125.
Tissue type Sample type
No. of samples
tested
No. (%) of HPV-
125 positive
samples
Mucosal
Genital warts 71 0 (0)
Laryngeal papillomas 85 0 (0)
Cervical cancer 104 0 (0)
Cutaneous
Common warts 102 2 (1.96)
Squamous cell
carcinoma of the skin
52 0 (0)
Basal cell carcinoma
of the skin
49 0 (0)
Hair follicles 138 1 (0.72)
Total 601 3 (0.50)
doi:10.1371/journal.pone.0022414.t002
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genotypes, including HPV-2, HPV-3, HPV-7, HPV-10, HPV-27,
HPV-28, HPV-29, HPV-40, HPV-43, HPV-77, HPV-78 and
HPV-91 in concentrations of 10
7–10
8 viral copies per reaction.
Because phylogenetic relationships between HPV genotypes do not
necessarily always reflect their tissue tropism, and to assess the clinical
significance of HPV-125, a representative collection of HPV-associated
benign and malignant neoplasms and hair follicles were tested for the
presence of HPV-125 using type-specific RT-PCR. The sample
collection was chosen to represent various sites of HPV infection
(mucosal/cutaneous) and possible outcomes of HPV infection (benign/
malignant lesions)(Table 2). The panel of samples thus included the
most important HPV-associated malignant neoplasms of mucosal
( c e r v i c a ls q u a m o u sc e l lc a r c i n o ma) and cutaneous (SCC and BCC of
skin) origin, the most important HPV-associated benign neoplasms of
mucosal (genital warts, laryngeal papillomas) and cutaneous (common
warts) origin and, in addition, hair follicles known to be a main
reservoir of usually harmless ‘commensal’ HPV genotypes in immuno-
competent individuals [27,32].
As shown in Table 2, none of the 260 mucosal samples tested
(cervical carcinomas, genital warts and laryngeal papillomas) were
positive for HPV-125. These findings indicate that HPV-125, in
agreement with its phylogenetic placement within Alphapapilloma-
virus species 2, does not exhibit mucosal tropism.
Of the 102 samples of common warts tested, two samples (1.96%)
contained HPV-125, indicating the cutaneous tropism of this
genotype (Table 2). In the first sample, due to the presence of
Betapapillomavirus genotypes HPV-8 and HPV-22, both known to be
cutaneous HPV genotypes, the development of this common wart
could not conclusively be attributed to HPV-125. In contrast, in the
second sample, HPV-125 was the only HPV genotype detected,
despite the use of several HPV genotyping assays, targeting a range
of Alphapapillomavirus and Betapapillomavirus genotypes, which sup-
ports the causative role of HPV-125 in the development of this
common wart (Table 3). In addition, in both HPV-125 positive
common warts, a very high HPV-125 viral load was observed,
indicating the presence of productive HPV-125 infection.
HPV-125 was not detected in any of the 101 samples of
malignant tumors of the skin tested. This finding may be due
either to the lack of HPV-125 potential for malignant transfor-
mation, or to the rarity of this genotype in immuno-competent
individuals. The results obtained indicate that HPV-125 does not
seem to be an important non-melanoma skin cancer causing
genotype, although the possibility of HPV-125 contributing to the
development of malignant skin lesions in immuno-compromised
individuals cannot be finally excluded, due to the rarity of the
genotype and the number of samples tested so far.
Of the 138 hair follicle samples tested, a single hair follicle
sample contained HPV-125. This sample also contained two
additional HPV genotypes, HPV-10 and HPV-36, consistent with
the current knowledge that HPVs are ubiquitous in hair follicles
and that hair follicles represent a viral reservoir in immuno-
competent individuals. Similarly to other members of Alphapapillo-
mavirus species 2, it is possible that HPV-125 is significantly more
frequent in immuno-compromised individuals [8–12,14,30];
however, this remains to be determined in further studies.
In conclusion, the characterization of the novel HPV genotype
HPV-125 improves our knowledge about the cutaneotrophic
Alphapapillomavirus species 2, which is phylogenetically nested deep
within the predominantly mucosotrophic Alphapapillomaviruses.
HPV-125 is a relatively rare HPV genotype with cutaneous
tropism, ethiologically linked with sporadic cases of common warts.
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